Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study

Bibliographic Details
Title:	Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Authors:	Choueiri, Toni K ^{a, *}, Merchan, Jaime R ^b, Figlin, Robert ^c, McDermott, David F ^d, Arrowsmith, Edward ^e, Michaelson, M Dror ^f, Tykodi, Scott S ^g, Heath, Elisabeth I ^h, Spigel, David R ⁱ, D’Souza, Anishka ^j, Kassalow, Laurent ^k, Perini, Rodolfo F ^k, Vickery, Donna ^k, Bauer, Todd M ^l
Source:	In The Lancet Oncology January 2025 26(1):64-73
Database:	ScienceDirect